BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 34411992)

  • 1. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic.
    Palmateer NE; Dickson E; Furrie E; Godber I; Goldberg DJ; Gousias P; Jarvis L; Mathie L; Mavin S; McMenamin J; McNeilly TN; Murcia P; Murray J; Reid G; Robertson C; Templeton K; von Wissmann B; Wallace LA; Waugh C; McAuley A
    Public Health; 2021 Sep; 198():102-105. PubMed ID: 34411992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey.
    McAuley A; Gousias P; Hasan T; Rashid L; Richardson C; Reid G; Templeton K; McGuire J; Wise H; McVicar L; Jenks S; Gunn R; Dickson E; Stock SJ; Stockton A; Waugh C; Wood R; McMenamin J; Robertson C; Goldberg DJ; Palmateer NE
    Public Health; 2021 Oct; 199():17-19. PubMed ID: 34517289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
    Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riding high: seroprevalence of SARS-CoV-2 after 4 pandemic waves in Manitoba, Canada, April 2020-February 2022.
    Duong S; Burtniak J; Gretchen A; Mai A; Klassen P; Wei Y; Loeppky C; Shaw SY; Bullard J; Van Caeseele P; Stein DR
    BMC Public Health; 2023 Dec; 23(1):2420. PubMed ID: 38053033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
    Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
    Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.
    Stringhini S; Wisniak A; Piumatti G; Azman AS; Lauer SA; Baysson H; De Ridder D; Petrovic D; Schrempft S; Marcus K; Yerly S; Arm Vernez I; Keiser O; Hurst S; Posfay-Barbe KM; Trono D; Pittet D; Gétaz L; Chappuis F; Eckerle I; Vuilleumier N; Meyer B; Flahault A; Kaiser L; Guessous I
    Lancet; 2020 Aug; 396(10247):313-319. PubMed ID: 32534626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis.
    Jahan N; Brahma A; Kumar MS; Bagepally BS; Ponnaiah M; Bhatnagar T; Murhekar MV
    Int J Infect Dis; 2022 Mar; 116():59-67. PubMed ID: 34968773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
    Moreira-Soto A; Pachamora Diaz JM; González-Auza L; Merino Merino XJ; Schwalb A; Drosten C; Gotuzzo E; Talledo M; Arévalo Ramirez H; Peralta Delgado R; Bocanegra Vargas S; Drexler JF
    mSphere; 2021 Dec; 6(6):e0068521. PubMed ID: 34817236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.
    Beaumont A; Durand C; Ledrans M; Schwoebel V; Noel H; Le Strat Y; Diulius D; Colombain L; Médus M; Gueudet P; Mouly D; Aumaître H
    BMJ Open; 2021 Nov; 11(11):e053201. PubMed ID: 34815286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of SARS-CoV-2 specific Immunoglobin G antibodies in rural population of Western Maharashtra, India.
    Agarwal D; Patil R; Roy S; Kaur H; Mehandale S; Bavdekar A; Nair H; Juvekar S; Dayma G;
    J Glob Health; 2023 Apr; 13():06011. PubMed ID: 37079274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of SARS-CoV-2 infection in the general population of Nepal during the first and second generalized waves of the COVID-19 pandemic-2020-2021.
    Paudel KP; Samuel R; Jha R; Pandey BD; Edirisuriya C; Shrestha NL; Gyawali P; Pokhrel A; Shrestha L; Mahato RK; Hossain SS; Arunkumar G; Bose AS; Dhimal M; Gautam D; Neupane S; Thakur N; Shrestha S; Bhusal N; Jha P; Gupta BP; Rayamajhi RB; Subedi KC; Kandel S; Poudel M; Thapa LB; Sharma GN; Gocotano AE; Sunny AK; Gautam R; Bhatta DR; Awale BK; Roka B; Ojha HC; Baral P; Adhikari MD; Lohani GR; Shrestha M; Singh DR; Aryal L; Pandav RS; Pokhrel R
    Influenza Other Respir Viruses; 2023 Dec; 17(12):e13234. PubMed ID: 38149926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada.
    Skowronski DM; Kaweski SE; Irvine MA; Kim S; Chuang ESY; Sabaiduc S; Fraser M; Reyes RC; Henry B; Levett PN; Petric M; Krajden M; Sekirov I
    CMAJ; 2022 Dec; 194(47):E1599-E1609. PubMed ID: 36507788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
    Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
    JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community-Based Seroprevalence of SARS-CoV-2 Antibodies following the First Wave of the COVID-19 Pandemic in Jazan Province, Saudi Arabia.
    Alhazmi A; Alamer E; Abdelwahab S; Khamjan N; Hamami A; Haddad M; Darraj M; Hashem AM; Algaissi A
    Int J Environ Res Public Health; 2021 Nov; 18(23):. PubMed ID: 34886175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.